EGFR and non-small cell lung carcinoma: The trial was stopped prematurely in April 2011 due to compelling evidence from other studies that NSCLC patients should be selected to first-line EGFR TKI therapy based on the presence of activating EGFR mutations, and that patients with tumors showing wild-type EGFR may be have inferior outcome when treated with first-line EGFR TKI as compared to chemotherapy.